sarpogrelate has been researched along with Arteriosclerosis, Coronary in 5 studies
sarpogrelate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for 6 months." | 5.24 | Effect of sarpogrelate, a selective 5-HT ( Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ, 2017) |
| "Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis." | 2.71 | Sarpogrelate treatment reduces restenosis after coronary stenting. ( Fujita, M; Ho, M; Ishii, K; Miki, O; Miwa, K; Miyamoto, A; Mizuno, K; Tsukahara, R, 2003) |
| "Sarpogrelate was administered to 22 of 33 patients with SEA in addition to aspirin therapy, and platelet aggregation, plasma serotonin concentration, and plasma plasminogen activator inhibitor (PAI) activity were measured before and 1 week after administration." | 1.37 | Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina. ( Kajiwara, I; Miyamoto, S; Ogawa, H; Soejima, H, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, DH | 1 |
| Chun, EJ | 1 |
| Hur, JH | 1 |
| Min, SH | 1 |
| Lee, JE | 1 |
| Oh, TJ | 1 |
| Kim, KM | 1 |
| Jang, HC | 1 |
| Han, SJ | 1 |
| Kang, DK | 1 |
| Kim, HJ | 1 |
| Lim, S | 1 |
| Kajiwara, I | 1 |
| Soejima, H | 1 |
| Miyamoto, S | 1 |
| Ogawa, H | 1 |
| Fujita, M | 1 |
| Mizuno, K | 1 |
| Ho, M | 1 |
| Tsukahara, R | 1 |
| Miyamoto, A | 1 |
| Miki, O | 1 |
| Ishii, K | 1 |
| Miwa, K | 1 |
| Hayashi, T | 1 |
| Sumi, D | 1 |
| Matsui-Hirai, H | 1 |
| Fukatsu, A | 1 |
| Arockia Rani P, J | 1 |
| Kano, H | 1 |
| Tsunekawa, T | 1 |
| Iguchi, A | 1 |
| Kandabashi, T | 1 |
| Shimokawa, H | 1 |
| Mukai, Y | 1 |
| Matoba, T | 1 |
| Kunihiro, I | 1 |
| Morikawa, K | 1 |
| Ito, M | 1 |
| Takahashi, S | 1 |
| Kaibuchi, K | 1 |
| Takeshita, A | 1 |
2 trials available for sarpogrelate and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effect of sarpogrelate, a selective 5-HT
Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomograph | 2017 |
Sarpogrelate treatment reduces restenosis after coronary stenting.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cell Division; Coronary Angiography; | 2003 |
3 other studies available for sarpogrelate and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina.
Topics: Adult; Aged; Angina, Stable; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pl | 2011 |
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
Topics: Acetylcholine; Animals; Antioxidants; Aorta, Thoracic; Biomarkers; Blood Proteins; Cholesterol, HDL; | 2003 |
Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Coronary Artery Disease; Dose-Response Relationship, | 2002 |